Progress of HDAC inhibitor panobinostat in the treatment of cancer

Current Drug Targets

Volumn 15, Issue 6, 2014, Pages 622-634

  Li, Xiaoyang ^a   Zhang, Jian ^a   Xie, Yuanchao ^a   Jiang, Yuqi ^a   Yingjie, Zhang ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Combined therapy; Hematologic malignancies; Histone deacetylase inhibitors; Monotherapy; Panobinostat; Solid tumors

Indexed keywords

PANOBINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; MONOTHERAPY; NEOPLASM; REVIEW; SOLID TUMOR; CLINICAL TRIAL (TOPIC); NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899844914     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140306152642     Document Type: Review

References (96)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
2. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131-42.
3. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363:15-23.
4. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997; 389: 251-60.
5. Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010; 45: 2095-116.
6. Shi B, Xu W. The development and potential clinical utility of biomarkers for HDAC inhibitors. Drug Discov Ther 2013; 7: 129-36.
7. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7-17.
8. Zhang Y, Fang H, Jiao J, Xu W. The structure and function of histone deacetylases: the target for anti-cancer therapy. Curr Med Chem 2008; 15: 2840-9.
9. Gregoretti I, Lee Y-M, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17-31.
10. Stünkel W, Campbell RM. Sirtuin 1 (SIRT1) The Misunderstood HDAC. J Biomol Screen 2011; 16: 1153-69.
11. Wolffe AP, Jones PL, Wade PA. DNA demethylation. Proc Natl Acad Sci USA 1999; 96: 5894-6.
12. Nguyen CT, Weisenberger DJ, Velicescu M, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2--deoxycytidine. Cancer Res 2002; 62: 6456-61.
13. Miska EA, Karlsson C, Langley E, Nielsen SJ, Pines J, Kouzarides T. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J 1999; 18: 5099-107.
14. Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. Proc Natl Acad Sci U S A 1998; 95: 10493-8.
15. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
16. Yang P, Zhang L, Zhang Y, Zhang J, Xu W. HDAC6: Physiological function and its selective inhibitors for cancer treatment. Drug Discov Ther 2013; 7: 233-42.
17. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006; 12: 634-42.
18. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16:1111-20
19. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011; 64: 525-31.
20. Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003, 46: 5097-116.
21. Sternson SM, Wong JC, Grozinger CM, Schreiber SL. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org Lett 2001; 3: 4239-42.
22. Remiszewski SW, Sambucetti LC, Bair KW, et al. N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in vivo Antitumor Activity: Discovery of (2 E)-N-Hydroxy-3-[4-[(2-hydroxyethyl)[2-(1 Hindol-3-yl) ethyl] amino] methyl] phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003; 46: 4609-24.
23. Shultz MD, Cao X, Chen CH, et al. Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. J Med Chem 2011; 54: 4752-72.
24. Shao W, Growney JD, Feng Y, Wang P, Yan-Neale Y, Conner GO. Potent anticancer activity of the pan-deacetylase inhibitor panobinostat (LBH589) as a single agent in in vitro and in vivo tumor models. In: 99th American Association of Cancer Research Annual Meeting: 2008; Abstract 6244.
25. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009; 147: 97-101.
26. Scuto A, Kirschbaum M, Kowolik C, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-acute lymphoblastic leukemia cells. Blood 2008; 111: 5093-100.
27. Maiso P, Carvajal-Vergara X, Ocio EM, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-9.
28. Floris G, Debiec-Rychter M, Sciot R, Stefan C, et al. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. Clin Cancer Res 2009; 15: 4066-76.
29. Crisanti MC, Wallace AF, Kapoor V, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009; 8: 2221-31.
30. Di Fazio P, Montalbano R, Quint K, et al. The pan-deacetylase inhibitor panobinostat modulates the expression of epithelialmesenchymal transition markers in hepatocellular carcinoma models. Oncol Lett 2013; 5: 127.
31. Catalano MG, Pugliese M, Gargantini E, et al. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int J Cancer 2012; 130: 694-704.
32. Pettazzoni P, Pizzimenti S, Toaldo C, et al. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free Radic Biol Med 2011; 50: 313-22.
33. Kubo M, Kanaya N, Petrossian K, et al. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 2013; 137: 93-107.
34. Erlich R, Kherrouche Z, Rickwood D, et al. Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma. Br J Cancer 2011; 106: 107-15.
35. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90.
36. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 2009; 280: 233-41.
37. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3.
38. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721.
39. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-10.
40. De Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 6663-73.
41. Undevia S, Janisch L, Schilsky R, et al. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. J Clin Oncol 2008; 26(suppl): abstr 14514.
42. Brunetto AT, Ang JE, Lal R, et al. First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res 2013; 19: 5494-504.
43. Siu LL, Pili R, Duran I, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1940-7.
44. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 23: 3912-22.
45. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3: 5.
46. Chavez-Blanco A, Segura-Pacheco B, Perez-Cardenas E, et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol cancer 2005; 4: 22.
47. Jiao J, Fang H, Xu W. Novel N-hydroxybenzamide histone deacetylase inhibitors as potential anti-cancer agents. Drug Discov Ther 2008; 2: 211.
48. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-28.
49. Campas-Moya C. Romidepsin for the treatment of cutaneous Tcell lymphoma. Drugs Today (Barc) 2009; 45: 787.
50. Shao W, Growney JD, Feng Y, et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer 2010; 127: 2199-208.
51. Ellis L, Pan Y, Smyth GK, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-10.
52. Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and-naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur J Cancer 2013; 49: 386-94.
53. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-76.
54. Vilas-Zornoza A, Agirre X, Abizanda G, et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012; 26: 1517-26.
55. Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12: 4628-35.
56. Younes A, Sureda A, Ben-Yehuda D, Ong T, Tan D. Phase II Study of Oral Panobinostat in Patients with Relapsed/refractory Hodgkin Lymphoma after High-dose Chemotherapy with Autologous Stem Cell Transplant. Haematologica 2009; 94: 34.
57. Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest 2011; 29: 451-5.
58. Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and-naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013; 49: 386-94.
59. Younes A, Ong T, Ribrag V, et al. Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. In: Blood (ASH Annual Meeting Abstracts): 2009; 2009: 923.
60. Gore SD. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res 2009; 33: S2-S6.
61. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-54.
62. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
63. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
64. Lucifero D, La Salle S, Bourc'his D, Martel J, Bestor TH, Trasler JM. Coordinate regulation of DNA methyltransferase expression during oogenesis. BMC Dev Biol 2007; 7: 36
65. Samuels BL, Herndon J, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma. Cancer 1998; 82: 1578-84.
66. Xiong Y, Dowdy SC, Podratz KC, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res 2005; 65: 2684-9.
67. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 2008; 113: 1596-604.
68. Fiskus W, Buckley K, Rao R, et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 2009; 8: 939-50.
69. Uy G, Abboud C, Cashen A. Phase I study of panobinostat plus decitabine in elderly patients with advanced MDS or AML. In: ASH Annual Meeting Abstracts: 2010; 2010: 1060.
70. Tan P, Reed K, Walker P, et al. Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study. In: Blood (ASH Annual Meeting Abstracts): 2011; 2011: 1529.
71. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao T-P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-38.
72. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 2008; 94: 283-6.
73. Jiang X-J, Huang K-K, Yang M, et al. Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-αB pathways. Cancer Lett 2012; 326: 135-42.
74. Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and--tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-9.
75. San-Miguel J, Sezer O, Siegel D, et al. A phase IB, multicenter, open-label dose-escalation study of oral panobinostat (LBH589) and IV bortezomib in patients with relapsed multiple myeloma. Blood 2009; 114: 1481-2.
76. Wang H, Cao Q, Dudek AZ. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res 2001; 32: 1027-31.
77. Underiner T, Ruggeri B, Gingrich D. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004; 11: 731-45.
78. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011; 13: 103-111.
79. Bug G, Ritter M, Wassmann B, et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 2005; 104: 2717-25.
80. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584. Cancer Res 2004; 64: 6626-34.
81. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002; 21: 427.
82. Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 2002; 19: 77-81.
83. Drappatz J, Lee E, Hammond S, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107: 133-8.
84. Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107: 1149-55.
85. Yazbeck VY, Buglio D, Georgakis GV, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008; 36: 443-50.
86. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 2007; 33: 78-84.
87. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169: 2171-80.
88. Kawamata N, Chen J, Koeffler HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007; 110: 2667-73.
89. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012; 119: 4017-25.
90. Younes A, Copeland A, Fanale M, Fayad L, Romaguera J, Kwak L. Safety and efficacy of the novel combination of Panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. In: ASH Annual Meeting Abstracts: 2011; 2011: 3718.
91. Kumar S, Mikhael J, LaPlant B, et al. Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. In: Blood (ASH Annual Meeting Abstracts): 2011; 2011: 2682.
92. Berenson J, Yellin O, Boccia RV, Nassir Y, Rothstein S, Swift R. A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood 2009; 114: 1855.
93. Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010; 66: 181-9.
94. Jones SF, Infante JR, Thompson DS, et al. A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 2012; 70: 471-5.
95. Bhatia R, Snyder D, Lin A, et al. A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR. In: Blood (ASH Annual Meeting Abstracts): 2009; 2009: 2194.
96. Christian B, Kopko A, Fehniger, T, Bartlett N, Blum K. A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). In: Blood (ASH Annual Meeting Abstracts): 2012; 2012: 1644.